Document is current

Chapter History

First Online: 23 March 2023

Financial Disclosure and Competing Interests

: This work was supported by grants R00MH121355 (J.J.D.) and R01MH117293 (C.B.N) from the National Institute of .

: Dr. Nemeroff’s financial disclosures are as follows: Dr. Nemeroff has provided consulting to ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Sage, BioXcel Therapeutics, SILO Pharma, XW Pharma, Neuritek, Engrail Therapeutics, Inc., Corcept Therapeutics Pharmaceuticals Company, SK Life Science Inc, Alfasigma, and Pasithea Therapeutics Corp. Dr. Nemeroff holds stock in the following companies: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, and TRUUST . Dr. Nemeroff serves on the scientific advisory board of ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), and Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia , Heading Health, TRUUST , and Pasithea Therapeutics Corp. He is on the Board of Directors at Gratitude America, ADAA, and Xhale Smart, Inc. Dr. Nemeroff holds the following patents: method and devices for transdermal delivery of lithium (US 6,375,990B1) and method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).